In the United States a plethora of pharmacological treatments from an array of drug classes are available to patients with major depressive disorder (MDD), a highly drug-treated condition. Though the MDD drug market is highly entrenched with generic therapies, MDD patients’ heterogeneous responses to antidepressants and/or atypical antipsychotics afford branded drugs (e.g., Trintellix [Lundbeck / Takeda], Rexulti [Otsuka / Lundbeck]) the opportunity to be introduced into the treatment paradigm, often as later-line therapies. Given MDD’s highly crowded and competitive landscape, it is valuable for drug marketers and developers to understand how MDD patients are being treated using real-world data.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Real world data: Longitudinal patient-level claims data analysis
Key companies: Allergan, Eli Lilly, Lundbeck, Otsuka, Sunovion, Takeda
Key drugs: Aripiprazole (Abilify, aripiprazole), citalopram (Celexa, generics), duloxetine (Cymbalta, generics), Fetzima, Latuda, Rexulti, Trintellix, Viibryd
Key analysis provided: